SARS-CoV-2 variants Omicron BA.4/5 and XBB.1.5 significantly escape T cell recognition

in solid organ transplant recipients vaccinated against the ancestral strain

3 Torin Halvorson^{1,2,3}, Sabine Ivison^{2,3}, Qing Huang^{2,3}, Gale Ladua^{1,4}, Demitra M. Yotis⁵, Dhirai 4 Mannar⁶, Sriram Subramaniam⁶, Victor H. Ferreira⁷, Deepali Kumar⁷, Sara Belga^{1,4,*}, and Megan 5 K. Levings^{2,3,8,*}, on behalf of the PREVenT study group 6 7 8 ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada ²Department of Surgery, University of British Columbia, Vancouver, BC, Canada 9 ³BC Children's Hospital Research Institute, Vancouver, BC, Canada 10 ⁴Vancouver Coastal Health Research Institute, Vancouver BC, Canada 11 ⁵Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada 12 ⁶Department of Biochemistry and Molecular Biology, University of British Columbia, 13 Vancouver, BC, Canada 14 ⁷Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada 15 ⁸School of Biomedical Engineering, University of British Columbia, Vancouver BC, Canada 16 *These authors contributed equally 17 18 19 20 Correspondence information: mlevings@bcchr.ca Megan Levings: BC Children's Hospital Research Institute, 950 West 28th Ave, Vancouver BC, 21 22 23 Word count for the abstract: 248/250 Word count for the main text: 3875/4000 24 Number of tables: 2 25 26 Number of figures: 6 Number of references: 67 27 28 Keywords: vaccine, COVID-19, T cell, solid organ transplantation, activation-induced marker 29

35

1

37

38

39

40

41

42

43

44

45

46

47

48

49

52

53

67 68

AUTHORSHIP PAGE Author Contributions TH research design, paper writing, performance of the research, data analysis, statistical analyses SI research design, paper writing, data analysis **QH** research design, performance of the research GL performance of the research, data analysis **DY** performance of the research, data analysis **DM** research design, performance of the research, paper writing SS research design, paper writing VHF data analysis, research design **DK** research design **SB** research design, performance of the research MKL research design, paper writing 50 51 **Disclosures:** D.K. has received consulting fees from Roche, GSK, Exevir and clinical trials grants from GSK. S. B. has received consultant fees from AstraZeneca and GSK, honoraria from Merck and research funding from Takeda. The remaining authors have no relevant conflicts to 54 disclose. 55 56 57 **Funding:** This work was supported by a grant from Public Health Agency of Canada / COVID-19 58 Immunity Task Force (AWD-019932 PHACA 2021) and the Canadian Institutes of Health 59 Research (HUI-159423). MKL holds a salary award from the BC Children's Hospital Research 60 Institute and a Tier 1 Canada Research Chair in Engineered Immune Tolerance. This study was 61 coordinated by the Canadian Donation and Transplantation Research Program (CDTRP). 62 63 64 65 66

- 69 Abbreviations
- 70 AIM, activation-induced marker
- 71 BA.4/5, Omicron BA.4 and BA.5 variants
- 72 COVID-19, coronavirus disease of 2019
- 73 DMSO, dimethyl sulfoxide
- 74 ICS, intracellular cytokine staining
- 75 IQR, interquartile range
- 76 IFN-γ, interferon-γ
- 77 IL-2, interleukin-2

- 78 mRNA, messenger RNA
- 79 nAb, neutralizing antibody
- 80 PBMCs, peripheral blood mononuclear cells
- 81 RBD, receptor-binding domain
- 82 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
- 83 SOTR, solid organ transplant recipient

Abstract 85 Background 86 Immune-suppressed solid organ transplant recipients (SOTRs) display impaired humoral 87 responses to COVID-19 vaccination, but T cell responses are incompletely understood. The 88 highly infectious SARS-CoV-2 variants Omicron BA.4/5 and XBB.1.5 escape neutralization by 89 90 antibodies induced by vaccination or infection with earlier strains, but T cell recognition of these lineages in SOTRs is unclear. 91 Methods 92 We characterized Spike-specific T cell responses to ancestral SARS-CoV-2, Omicron BA.4/5 and 93 XBB.1.5 peptides in a prospective study of kidney, lung and liver transplant recipients (n = 42) 94 throughout a three- or four-dose ancestral Spike mRNA vaccination schedule. Using an 95 optimized activation-induced marker assay, we quantified circulating Spike-specific CD4+ and 96 CD8+ T cells based on antigen-stimulated expression of CD134, CD69, CD25, CD137 and/or 97 98 CD107a. 99 Results Vaccination strongly induced SARS-CoV-2-specific T cells, including BA.4/5- and XBB.1.5-100 reactive T cells, which remained detectable over time and further increased following a fourth 101 dose. However, responses to Omicron BA.4/5 and XBB.1.5 were significantly lower in 102 magnitude compared to ancestral strain responses. Antigen-specific CD4+ T cell frequencies 103 correlated with anti-receptor-binding domain (RBD) antibody titres, with post-second dose T cell 104 responses predicting subsequent antibody responses. Patients receiving prednisone, lung 105 transplant recipients and older adults displayed weaker responses. 106 107 Conclusions Ancestral strain vaccination stimulates BA.4/5 and XBB.1.5-cross-reactive T cells in SOTRs, but 108 responses to these variants are diminished. Antigen-specific T cells can predict future antibody 109 responses and identify vaccine responses in seronegative individuals. Our data support 110 monitoring both humoral and cellular immunity in SOTRs to track effectiveness of COVID-19 111

vaccines against emerging variants.

112

Introduction

- 115 COVID-19 vaccines effectively reduce infections, hospitalizations and mortality from SARS-
- 116 CoV-2¹⁻³. However, immune-suppressed populations such as solid-organ transplant recipients
- 117 (SOTRs), who require lifelong immune-suppressive therapy to prevent allograft rejection, remain
- at elevated risk from COVID-19 despite vaccination⁴. SOTRs display impaired humoral
- immunity to COVID-19 vaccination, with decreased anti-Spike binding and neutralizing
- antibody (nAb) responses compared to the general population⁵⁻⁸. However, a third or fourth
- 'booster' dose significantly increases seropositivity and nAbs in SOTRs^{6,9,10}.
- As SARS-CoV-2 continues to evolve, emerging variants, including Omicron lineages and their
- derivatives, continue to challenge global COVID-19 immunity^{11–15}. The Omicron BA.4 and
- BA.5 (henceforth BA.4/5) subvariants display over 40 Spike protein mutations and enhanced
- affinity for the ACE2 receptor^{13,16}. More recently, recombinant BA.2-derived XBB lineages have
- emerged, with XBB.1.5 the latest to dominate globally 14,15,17,18. These subvariants are highly
- infectious and evade neutralization by vaccination- or infection-induced nAbs targeting the
- ancestral strain¹⁶. Neutralization of XBB lineages is reduced more than 100-fold relative to
- ancestral SARS-CoV-2, even after vaccination with BA.4/5 bivalent vaccines^{17–20}.
- 130 Cellular immunity to SARS-CoV-2 in SOTRs is less well understood. SARS-CoV-2-specific T
- cell responses are widely recognized to be critical in mitigating severe COVID-19 disease^{21–23},
- with CD4+ and CD8+ responses correlating negatively with disease severity²⁴ and breakthrough
- infection risk post-vaccination²⁵. Furthermore, memory T cells cross-recognize emerging
- variants, including Omicron and the BA sublineages^{18,25–27}. However, SOTRs display poor
- cellular responses to vaccination, with lower Spike-specific CD4+ and CD8+ T cell frequencies
- compared to healthy controls two weeks and six months after two-dose vaccination^{25,28}.
- 137 Vaccination also induces comparatively weaker Spike-specific IFN-γ+ and/or IL-2+ T cell
- responses than natural infection in SOTRs^{29,30}.
- While it is well-established that BA.4/5 and XBB.1.5 escape antibody neutralization, whether
- vaccination against the ancestral strain induces T cell responses cross-recognizing these variants
- is unclear in SOTRs. A recent study assessed T cell responses to a fourth mRNA vaccine dose by
- intracellular cytokine staining (ICS) in a small cohort of SOTRs, finding that a fourth dose
- significantly increased frequencies of IFN-γ+/IL-2+ BA.4/5-specific CD4+, but not CD8+, T
- 144 cells⁹. Only one study has directly compared ancestral SARS-CoV-2- and BA.4/5-specific T cell
- responses in SOTRs, showing no differences in magnitude by ICS³¹. However, ICS does not
- quantify the full diversity of antigen-specific T cells^{32,33}. Alternatively, activation-induced marker
- 147 (AIM) assays leverage T cell surface protein upregulation in response to antigen-specific
- stimulation, broadly quantifying antigen-specific T cells independently of proliferation or
- cytokine production^{32–35}. Indeed, AIM assays are increasingly used to assess T cell responses to
- 150 SARS-CoV-2 infection and vaccination^{24,27,28,36}.
- Here, we used the AIM method to characterize vaccine-induced SARS-CoV-2-specific T cells in
- a prospective cohort of 42 liver, kidney and lung transplant recipients. Of specific interest was

- whether vaccination against the SARS-CoV-2 ancestral strain would stimulate T cells with cross-
- reactivity to Omicron BA.4/5 and/or XBB.1.5.

Methods (see also Extended Methods)

157 Study Design and Enrollment

155156

169

185

186 187

- 158 The PREVenT-COVID study is a Canadian prospective study of vaccine immunogenicity in
- SOTRs across seven tertiary care transplant centres^{9,37}. This study of cell-mediated immunity
- was conducted at the University of British Columbia (UBC) with approval from the UBC
- 161 Research Ethics Board (H21-01269). Adult SOTRs provided informed consent and were enrolled
- at first dose of an approved monovalent COVID-19 mRNA vaccine, BNT162b2 (Pfizer-
- BioNTech,) or mRNA-1273 (Moderna), beginning January 2021. Whole blood was drawn from
- participants within 2 weeks prior to the second dose, 3-6 weeks post-second dose, 6 months post-
- 165 first dose, 3-6 weeks post-third dose and one year post-first dose. One-year samples served as
- post-fourth dose (3-6 weeks) samples in a subset of patients. PBMCs were collected from blood
- samples and cryopreserved at -80°C. Participants were to inform the study team if they
- developed COVID-19 for confirmation via PCR or rapid antigen test.
- 170 Activation-Induced Marker Assays
- 171 SARS-CoV-2 ancestral strain (PM-WCPV-S-1, JPT) and Omicron BA.4/5 (PM-SARS2-
- SMUT10-1, JPT) overlapping peptide pools corresponding to the complete Spike proteins were
- aliquoted in 30% DMSO and stored at -80°C. Cryopreserved PBMCs were thawed into 37°C
- 174 Immunocult XF (10981, STEMCELL) with 1% penicillin/streptomycin and 50 U/mL benzonase
- 175 (70664-3, Novagen). PBMCs were rested overnight at 37°C in Immunocult XF with 1%
- penicillin/streptomycin and stimulated for 20 h at 4-5x10⁵ cells per condition in 200 uL with 1
- 177 µg/mL SARS-CoV-2 ancestral strain or BA.4/5 Spike peptides, equimolar dimethyl sulfoxide
- 178 (DMSO, 0.12%), Fluzone® Quadrivalent influenza vaccine (2.5%) (Sanofi-Pasteur) or Cytostim
- (0.05%) (130-092-172, Miltenyi). CD4 and CD107a staining antibodies were added during
- stimulation, with surface staining for CD3, CD4, CD8, CD25, CD69, CD134, and CD137 after
- stimulation. Data were acquired on an LSR Fortessa (BD) flow cytometer on high-throughput
- sampler (HTS) mode. Antigen-specific CD4+ T cells were defined as CD134+/CD25+,
- 183 CD134+/CD69+ or CD137+/CD69+ while antigen-specific CD8+ T cells were defined as
- 184 CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+, as previously described^{24,38–46}.
 - Whole protein stimulations were performed with protein isolates (**Extended Methods**) from ancestral SARS-CoV-2 or XBB1.5 at $0.5 \mu g/mL$, equivolumetric PBS, $1 \mu g/mL$ ancestral strain peptides or 0.05% Cytostim for 44 h.
- 190 Data Analysis
- Data were analyzed using FlowJo v10.8.1 and GraphPad Prism v10.0.0. Antigen-specific T cells
- were quantified as the percentage of CD4+ or CD8+ T cells expressing each AIM marker, after
- subtracting the frequency of AIM+ cells in the equivalent unstimulated condition. Net AIM
- 194 frequencies less than 0.005%, considered the limit of detection for the assay, were set to equal
- 195 0.005% to avoid negative or zero values. Samples with fewer than 10 000 total CD4+ or CD8+ T
- cells were excluded. AIM responses were compared across timepoints using a mixed-effects
- analysis (REML) on log₂-transformed data, assuming sphericity, with post-hoc Dunnett's

multiple comparisons test. Patients who received a fourth dose or contracted COVID-19 were initially excluded to assess the duration of vaccine-induced T cell immunity.

Responses at one year were compared within (paired Wilcoxon tests) and between (Kruskal-Wallis test with Dunn's multiple comparisons) control, post-fourth dose (within 3-6 weeks) and hybrid (fourth dose and contracted COVID-19) groups. Post-third dose BA.4/5 and XBB.1.5 responses were compared to the ancestral strain by paired Wilcoxon tests. Post-third dose AIM responses between groups defined by clinical parameters were compared using Mann-Whitney and Kruskal-Wallis tests as appropriate. Semilogarithmic regression analysis modelled the continuous effects of age and time since transplantation on post-third dose AIM responses.

Spearman's correlations assessed relationships between post-third dose T cell AIM responses and published serum anti-RBD titres from the same individuals⁹. In patients with undetectable anti-RBD antibodies post-second dose, log-log regression modelled the relationship between post-second dose CD4+ AIM responses and post-third dose anti-RBD antibodies. Post-third dose BA.4/5-specific AIM responses were compared between individuals with and without detectable BA.4/5-neutralizing antibodies⁹ by paired t-tests on log₂-transformed AIM+ frequencies.

Results

198

199 200 201

202

203

204

205

206

207208

209

210

211

212

213214

- 217 Study Population
- 218 The study cohort consisted of 42 SOTRs with a median age of 58 (IQR 47-56), of which 22
- 219 (52%) were female and 20 (48%) were male (**Table 1**, **Figure S1**). Subjects were recipients of
- kidney (n = 16), liver (n = 16) or lung (n = 10) transplants. Median time since transplantation
- was 6.8 years (IQR 3.1-12.9). All subjects received at least two doses of monovalent Pfizer-
- BioNTech BNT162b2 or Moderna mRNA-1273 COVID-19 vaccines. As one-year samples were
- collected soon (3-6 weeks) after patients received a fourth dose, subjects were grouped as neither
- having contracted COVID-19 nor received a fourth dose (controls, n = 6), post-fourth dose (n = 6)
- 225 15), post-fourth dose and contracted COVID-19 ('hybrid', n = 7) or contracted COVID-19 only
- (n = 4). At enrollment, all patients were receiving at least one immune-suppressive drug, with
- tacrolimus (35/42, 83%) mycophenolate mofetil or mycophenolate sodium (27/42, 64%) and
- prednisone (20/42, 48%) being the most frequent.
- 229 *COVID-19* vaccination induces significant and durable BA.4/5-specific T cell responses in solid-
- 230 organ transplant recipients
- We assessed T cell AIM responses following stimulation with SARS-CoV-2 ancestral strain or
- BA.4/5 peptides throughout a 3-4 dose COVID-19 vaccination schedule (Figure 1A). Antigen-
- 233 specific CD4+ T cells (CD134+/CD25+, CD134+/CD69+ or CD137+/CD69+) and CD8+ T cells
- 234 (CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+) were quantified (**Figure 1B, Figure**
- S2). Ancestral- and BA.4/5-specific CD4+ AIM responses increased significantly after a second
- dose (p < 0.0001) but trended lower at six months (Figure 1C). A third dose induced significant
- responses that remained elevated above pre-second dose levels at one year (p < 0.0001). Similar
- results were observed for CD8+ T cell responses, but with lower AIM+ frequencies and
- substantial heterogeneity between donors (Figure 1C). However, post-third dose responses to
- ancestral SARS-CoV-2 were significant for all CD8 AIM markers analyzed, and BA.4/5-specific

- 241 CD137+/CD69+ responses were significant at post-second dose, post-third dose and one-year
- 242 timepoints.
- As a control, we measured CD4+ and CD8+ responses to an inactivated influenza vaccine
- 244 (Fluzone® Quadrivalent, Sanofi-Pasteur) at the same timepoints (Figure S3A, B, C). COVID-19
- vaccination induced no changes in influenza-specific T cell responses, supporting the specificity
- of our assays. Furthermore, cryopreserved replicate PBMC aliquots from two healthy controls
- showed stable AIM responses over several months (Figure S4), demonstrating low technical
- variation of the assay. For simplicity, we focused further analyses on CD134+/CD69+ CD4+ T
- cell responses, and CD137+/CD69+ CD8+ T cell responses, as these AIMs are widely
- used^{24,33,44,45,47–49} and showed the strongest trends across vaccination timepoints.
- 251 A fourth monovalent ancestral vaccine dose boosts BA.4/5-specific T cell responses
- A subset of patients received a fourth dose 3-6 weeks prior to one-year sample collection, with
- some additionally contracting COVID-19 (hereafter 'hybrid') (Figure 2A), allowing us to ask if
- a 4th dose further increased BA.4/5-specific T cell immunity. Indeed, fourth dose recipients and
- 255 hybrid patients showed trending or significant increases above post-third dose levels in ancestral-
- and BA.4/5-specific CD4+ responses (Figure 2B), with these increases being significantly
- 257 greater than observed in controls who received no fourth dose (**Figure 2C**). No significant
- differences were identified between the fourth dose and hybrid groups.
- 259 T cell responses to Omicron BA.4/5 are lower in magnitude than responses to the ancestral strain
- Having established that second and third doses of the monovalent ancestral vaccine induce
- 261 BA.4/5-responsive CD4+ and CD8+ T cells, we next compared the magnitude of post-third dose
- 262 BA.4/5-specific AIM responses with ancestral strain responses. Among CD4+ T cells, responses
- to peptides from Omicron BA.4/5 were lower compared to ancestral SARS-CoV-2: median
- frequencies of CD134+/CD25+ (1.67-fold lower, Wilcoxon signed-rank test p <0.0001),
- 265 CD134+/CD69+ (1.38-fold lower, p < 0.0001), and CD137+/CD69+ (1.34-fold lower, p =
- 266 0.0022) were diminished (**Figure 3A**). Similar trends were observed among CD8+ T cells,
- particularly when comparing CD137+/CD69+ frequencies (1.45-fold lower, p = 0.0071) (**Figure**
- 268 **3B**).
- 269 Patients receiving prednisone, lung transplant recipients and older individuals display weaker T
- 270 cell responses
- We next sought to identify patient characteristics associated with weaker BA.4/5-specific AIM
- 272 responses, using post-third dose data for its large sample size and clinical relevance. Compared
- 273 to patients not receiving prednisone, patients on prednisone at baseline showed significantly
- lower CD4+ (1.53-fold lower, Mann-Whitney U-test p = 0.030) and CD8+ (3.36-fold lower, p = 0.030)
- 275 0.017) responses to BA.4/5, with similar trends for ancestral strain responses (**Figure 4A**). Since
- all lung and no liver recipients were receiving prednisone at baseline, we also compared
- 277 responses by organ type (**Figure 4B**), showing trending or significantly lower BA.4/5-specific
- 278 CD4+ AIM responses in lung transplant recipients compared to liver (4.97-fold lower, p =
- 279 0.0017) and kidney (3.23-fold lower, p = 0.0877), with similar results for ancestral responses
- (lung vs liver, 3.28-fold lower, p = 0.0029; lung vs kidney, 3.71-fold lower, p = 0.0161) (**Figure**
- **4B**). CD8+ AIM responses followed similar trends but were non-significant.

- Using semilogarithmic regression to model the effect of age on AIM responses, we identified
- significant declines in AIM responses with age (Figure 4C). The regression line slope was
- significantly different from zero for CD4+ ancestral- (y = -0.0108x + 0.0100, p = 0.0390) and
- BA.4/5-specific responses (y = -0.0127x + 0.0100, p = 0.0238), with even stronger relationships
- identified for CD8+ responses (ancestral, y = -0.0194x + 0.3949, p = 0.0146; BA.4/5, y = -0.0194x + 0.3949, p = 0.0146; BA.4/5, y = -0.0194x + 0.3949, p = 0.0146; BA.4/5, y = -0.0194x + 0.3949, p = 0.0146; BA.4/5, y = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0194x + 0.3949, p = 0.0146; BA.4/5, p = -0.0146; BA.4/5, p = -0.014
- 0.0267x + 0.6728, p = 0.0059). There were no significant differences in post-third dose AIM
- responses between males and females (Figure S5A), or between patients vaccinated primarily
- with Pfizer-BioNTech BNT162b2 compared to Moderna mRNA-1273 (Figure S5B).
- 290 *SARS-CoV-2-specific T cell responses correlate with circulating anti-Spike antibodies*
- We investigated correlations between CD4+ T cell AIM responses and previously published anti-
- 292 RBD binding antibody titres measured in the same individuals at the same timepoints⁹.
- 293 CD134+/CD69+ CD4+ T cell AIM responses correlated strongly with antibody levels (**Figure**
- 5A, Table 2). At pre- and post-second dose timepoints, there were weak to moderate correlations
- 295 with antibody titres for CD4+ T cell responses to ancestral SARS-CoV-2 (pre-second dose
- Spearman's r = 0.2369, p = 0.2884; post-second dose r = 0.3064, p = 0.0514) and BA.4/5 (pre-
- second dose r = 0.4066, p = 0.0604; post-second dose r = 0.3091, p = 0.0493). However, the
- 298 strength and significance of these correlations increased over time, even without additional
- 299 vaccinations, and were further enhanced by a third dose, for both responses to the ancestral strain
- 300 (six months r = 0.8028, p = 0.0082; post-third dose r = 0.6755, p < 0.0001) and BA.4/5 (six
- 301 months r = 0.6554, p = 0.0454; post-third dose r = 0.6411, p < 0.0001). By contrast, antibody
- 302 correlations with CD8+ AIM responses did not follow a clear trend and were only significant for
- post-third dose ancestral strain responses (r = 0.3527, p = 0.0441) (Figure 5A, Table 2).
- As a substantial proportion of patients showed strong T cell responses but no detectable antibody
- 305 titres post-second dose, we assessed whether post-second dose CD4+ T cell responses could
- predict subsequent post-third dose antibodies in these patients (n = 19). Log-log regression
- analysis identified a strong positive relationship, with patients who demonstrated stronger T cell
- responses to ancestral SARS-CoV-2 (y = 1.313x + 3.359, p < 0.0001) or BA.4/5 (y = 1.371x + 3.359)
- 3.518, p < 0.0001) subsequently showing stronger post-third dose antibody responses (**Figure**
- 310 **5B**). We also assessed the relationship of post-third dose T cell AIM responses with the presence
- or absence of BA.4/5-specific nAbs in a subset of patients (n = 18). Although only four patients
- developed nAbs post-third dose, there was a clear trend toward higher CD4+ and CD8 AIM+
- frequencies in these patients (Figure 5C). This trend was less apparent after a fourth dose.
- 314 Significant escape from T cell recognition by the novel variant XBB.1.5 in SOTRs
- We next asked whether three-dose ancestral COVID-19 vaccination induced T cells capable of
- 316 cross-recognizing the novel XBB.1.5 variant, using whole protein isolates in a subset of the
- study cohort (n = 10) for which we had additional pre-second dose and post-third dose PBMC
- samples. Although few XBB.1.5-specific T cells were observed prior to a second dose, three
- 319 COVID-19 vaccine doses significantly induced XBB.1.5-responsive CD4+ T cells (**Figure 6A**).
- 320 CD8+ AIM responses to XBB.1.5 were detected in only four of 10 patients after three doses.
- 321 CD4+ CD134+/CD69+ AIM responses to XBB.1.5 were significantly weaker than responses to
- ancestral SARS-CoV-2 at pre-second dose (5.0-fold lower, p = 0.0078) and post-third dose

- timepoints (2.0-fold lower, p = 0.0020) (Figure 6B). CD8+ CD137+/CD69+ AIM responses to
- XBB.1.5 clearly trended lower (4.8-fold lower, p = 0.0781) at the pre-second dose timepoint,
- with XBB.1.5 responses detectable in only two of ten patients (seven of ten patients responded to
- 326 the ancestral protein), and were significantly weaker than ancestral SARS-CoV-2 responses after
- three doses (18-fold lower, p = 0.0156) (Figure 6B).

Discussion

- 329 As SARS-CoV-2 variants continue to evolve, understanding vaccine immunogenicity in
- vulnerable populations is critical to informing vaccination strategies. SOTRs show impaired
- humoral and cellular responses to mRNA vaccines^{5,9,28,30}, corresponding with increased
- susceptibility to infection^{4,25}. In the present study, we have provided the first AIM based-
- characterization of COVID-19 vaccine-induced T cell responses in SOTRs. We demonstrate
- significant T cell responses to vaccination which persist over time and are enhanced by booster
- doses. Although monovalent vaccination with the ancestral strain induced T cells capable of
- cross-recognizing BA.4/5 and XBB.1.5, responses to these variants were weaker than those to
- 337 the ancestral strain.
- We observed strong induction of SARS-CoV-2-specific AIM responses to both ancestral SARS-
- CoV-2 and BA.4/5 by second and third doses of mRNA vaccine, particularly among CD4+ T
- 340 cells. Although responses trended lower over time at the six-month and one-year timepoints,
- 341 CD4+ T cell responses remained significantly elevated above pre-second dose levels and were
- further enhanced by a fourth dose. Our data confirm studies showing that SOTRs mount
- significant T cell responses to mRNA vaccination^{9,25,28,29,31}, and represent the first AIM-based
- characterization of BA.4/5-cross-reactive T cells in SOTRs. We show that even two-dose mRNA
- vaccination significantly induces BA.4/5 cross-reactivity, however, this declines over time and at
- least one additional (i.e. third) dose may be required to achieve lasting BA.4/5-specific T cell
- memory. Indeed, longitudinal analyses of immune-suppressed patients with diverse pathologies
- observe sharp declines in post-second dose responses^{28,50}, while responses remain stable at
- similar magnitudes to healthy individuals following third and fourth doses⁵⁰. Interestingly,
- 350 breakthrough infection did not appear to further enhance BA.4/5-specific responses in patients
- 351 who received a fourth dose, despite cases occurring during a global Omicron wave. Of note,
- 352 these infections occurred more than four months (IQR 111-148 days) prior to one-year sampling,
- 353 thus the acute T cell response to infection was likely not captured.
- We also established clinical factors associated with BA.4/5-specific T cell responses to
- vaccination. Although responses in patients taking prednisone were decreased, consistent with
- studies of BA.4/5 neutralization in SOTRs⁹, all lung recipients in our cohort, and no liver
- 357 recipients, were receiving prednisone in accordance with regional guidelines⁵¹. When analyzing
- differences between organ groups, lung recipients responded weakly compared to liver and
- kidney recipients. This is likely due to the more intense immunosuppression given to lung
- transplant recipients^{52,53}. Others have demonstrated impaired vaccine-induced IFN-γ responses
- and increased COVID-19 mortality in lung recipients^{5,54,55}. We also demonstrate a negative
- relationship between age and BA.4/5-specific AIM responses. CD8+ AIM responses showed

particularly strong declines with increasing patient age, congruent with greater susceptibility to

- ageing in CD8+ T cells than CD4+ T cells^{56–58}.
- 365 As CD4+ T cells promote high-affinity humoral responses and B cell memory⁵⁹, we analyzed
- 366 correlations of BA.4/5-specific AIM responses with anti-RBD and nAb titres⁹. Correlations
- between CD4+ AIM responses and anti-RBD titres were non-significant prior to a second dose,
- but increased in strength and significance with subsequent vaccinations, and over time even
- without additional vaccinations. At the six-month timepoint or after three doses, patients who
- developed antibody responses generally showed strong CD4+ AIM responses, suggesting that a
- third dose is necessary to optimally stimulate both immune compartments and that the
- 372 relationship between cellular and humoral immunity may also strengthen with time. However, a
- 373 substantial number of patients with no detectable anti-RBD titres after two or three doses showed
- 374 strong AIM responses, hinting that T cells could play a critical protective role in these antibody-
- deficient SOTRs^{21,60}. Furthermore, post-second dose T cell responses strongly predicted post-
- third dose antibody responses, supporting a causative relationship between antigen-specific
- 377 CD4+ T cells and humoral responses. We also observed trending associations between BA.4/5-
- 378 specific AIM responses and BA.4/5-nAbs, but these were non-significant as few patients
- 379 developed post-third dose BA.4/5-nAbs.
- The BA.4/5 and XBB.1.5 variants escape antibody-mediated neutralization in individuals
- vaccinated against the ancestral strain^{13,16–20,61}. CD4+ and CD8+ T cell responses have thus far
- shown conserved cross-reactivity with Omicron 18,26,27,62 including BA.4/5 in immune-
- compromised patients and SOTRs^{31,63}, but no data existed for T cell responses to XBB.1.5. In
- contrast to previous research, we found significant decreases in T cell recognition of BA.4/5
- relative to the ancestral strain. We are the first to investigate BA.4/5 cross-recognition in SOTRs
- using an AIM assay, which detects cytokine-negative T cells and rare populations with higher
- sensitivity than ICS^{33,34}, lending itself well to detecting small differences. We obtained similar
- results for XBB.1.5, showing strongly impaired T cell cross-recognition in monovalent ancestral-
- vaccinated SOTRs. However, despite their lower magnitude, CD4+ responses to BA.4/5 and
- 390 XBB.1.5 were induced by vaccination, consistent with broad epitope specificity of CD4+ T
- 391 cells⁶⁴, and displayed similar kinetics to ancestral responses. Thus, impairments in T cell cross-
- recognition may not severely impact vaccine immunogenicity for these variants. Large-scale
- 393 epidemiological data in SOTRs show significantly decreased incidence of hospitalization and
- death following the emergence of Omicron, suggesting adequate vaccine-mediated protection
- from severe outcomes in this highly transmissible but low-virulence variant⁴. The full impact of
- the recent wave of XBB.1.5 infections on SOTRs remains to be seen.
- Our study entails several inherent limitations. First, we are unable to draw conclusions regarding
- 398 the magnitude of AIM responses in SOTRs relative to the general population as we did not
- include healthy controls in the study. This also precludes the extension of novel findings, such as
- impaired T cell responses to BA.4/5 and XBB.1.5, beyond the SOTR population. Second, our
- sample size was insufficient to adequately assess effects of certain clinical parameters such as
- antimetabolite or tacrolimus use, or whether AIM responses predict subsequent infection or
- 403 hospitalization. Finally, our method provided more robust characterization of CD4+ T cell

- responses than CD8+ T cell responses. This may be a feature of the peptide mixes used, which
- 405 consist of 15-mers. CD4+ T cells recognize peptides from 11-20 amino acids, while CD8+ T
- 406 cells optimally recognize peptides of 8-11 amino acids⁶⁵. However, CD8+ T cell responses were
- also poorly detected using whole protein stimulation (Figure 6), and others have observed lower
- 408 magnitudes of Spike-specific CD8+ responses using diverse methods^{43,44,60,66,67}. Thus, CD8+ T
- cells may preferentially respond to non-Spike antigens, including internal viral proteins⁴⁴, and
- Spike-based assays may not capture the full complement of SARS-CoV-2-specific CD8+ T cells.
- Overall, we demonstrate that SOTRs mount significant BA.4/5-cross-reactive T cell responses to
- ancestral COVID-19 mRNA vaccines, with booster doses enhancing responses. However, using
- a sensitive AIM assay, we show that cross-recognition of BA.4/5 and XBB.1.5 is significantly
- 414 impaired in SOTRs. We also demonstrate strong correlations between CD4+ T cell responses and
- antibody responses, and identify weaker cellular responses in older adults and lung recipients
- receiving prednisone. Our data provide unique insights into the kinetics of variant-specific T cell
- responses in immune-compromised patients, with important implications for clinical and public
- 418 health guidelines.

Acknowledgements

- We wish to express our deepest gratitude to those who participated in this study. Finally, we wish
- 421 to thank Lisa Xu at the BC Children's Hospital Research Institute Flow Cytometry Core for her
- 422 invaluable assistance with data acquisition. The study was coordinated by the Canadian Donation
- and Transplantation Research Program.
- 424 **PREVenT COVID group investigators:** PREVenT COVID group investigators: Jean-Sébastien
- Delisle (Hôpital Maisonneuve Rosemont (HMR), Sasan Hosseini-Moghaddam (University
- 426 Health Network (UHN)), Dr. Héloïse Cardinal (Centre hospitalier de l'Université de Montréal
- 427 (CHUM)), Dr. Mélanie Dieudé (Centre hospitalier de l'Université de Montréal (CHUM)), Dr.
- Normand Racine (Institut de Cardiologie de Montréal (ICM)), Dr. Karina Top (Dalhousie
- 429 University), Dr. Gaston DeSerres (INSPQ, Public Health), Dr. Lori West (University of Alberta
- 430 (UofA), CDTRP)), Dr. Marc Cloutier (HémaQuébec), Dr. Renée Bazin (Héma-Québec), Dr.
- 431 Christopher Lemieux (Université Laval), Dr. Sacha De Serres (Université Laval), Dr. Atul
- Humar (University Health Network (UHN)), Dr. Sarah Shalhoub (London Health Sciences
- 433 Center (LHSC)), Dr. Dima Kabbani (University of Alberta (UofA)), Dr. Marie-Josée Hébert
- 434 (Centre hospitalier de l'Université de Montréal (CHUM)), Dr. Patricia Gongal (CDTRP),
- 435 Kristian Stephens (CDTRP).
- 436 **PREVenT COVID Group Coordinators:** Dr. Julie Turgeon (CHUM), Zineb Khrifi (CHUM),
- France Samson (Université Laval), Maryse Desjardins (ICM), Hélène Brown (ICM), Johanne
- Doiron (ICM), Cadence Baker (London Health Sciences Centre, LHSC), Taylor Toth (LHSC),
- Grant Luke (LHSC), Natalia Pinzon (UHN), Victoria G. Hall (UHN), Kimberly Robertson
- 440 (UofA), Heather Mangan (UofA).

References

- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- 2. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-
- regression. *Lancet*. 2022;399(10328):924-944. doi:10.1016/S0140-6736(22)00152-0
- 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- 451 4. Overvad M, Koch A, Jespersen B, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation—A Danish nationwide cohort study.
- 453 *Am J Transplant*. 2022;22(11):2627-2636. doi:10.1111/ajt.17142
- 5. Hamm SR, Møller DL, Pérez-Alós L, et al. Decline in Antibody Concentration 6 Months
- 455 After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients
- and Healthy Controls. *Front Immunol*. 2022;13. Accessed April 20, 2023.
- https://www.frontiersin.org/articles/10.3389/fimmu.2022.832501
- 6. Chang CC, Vlad G, Vasilescu ER, et al. Previous SARS-CoV-2 infection or a third dose of
- vaccine elicited cross-variant neutralising antibodies in vaccinated solid-organ transplant
- 460 recipients. Clin Transl Immunol. 2022;11(8):e1411. doi:10.1002/cti2.1411
- 7. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2
- mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA*. 2021;325(21):2204-
- 463 2206. doi:10.1001/jama.2021.7489
- 8. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a Single Dose of SARS-CoV-
- 2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*.
- 466 2021;325(17):1784-1786. doi:10.1001/jama.2021.4385
- 9. Ferreira VH, Ierullo M, Mavandadnejad F, et al. Omicron BA.4/5 neutralization and T-cell
- 468 responses in organ transplant recipients after Booster mRNA vaccine: a Multicenter Cohort
- Study. Clin Infect Dis Off Publ Infect Dis Soc Am. Published online March 28, 2023:ciad175.
- 470 doi:10.1093/cid/ciad175
- 10. Karaba AH, Johnston TS, Aytenfisu TY, et al. A Fourth Dose of COVID-19 Vaccine Does
- Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients
- With Suboptimal Vaccine Response. *Transplantation*. 2022;106(7):1440.
- 474 doi:10.1097/TP.0000000000004140
- 11. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
- 476 (B.1.1.529) Variant. N Engl J Med. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
- 12. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation
- and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants

- in England: a cohort study. *Lancet*. 2022;399(10332):1303-1312. doi:10.1016/S0140-
- 480 6736(22)00462-7
- 13. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2
- Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell*. 2022;185(14):2422-2433.e13.
- 483 doi:10.1016/j.cell.2022.06.005
- 484 14. Uriu K, Ito J, Zahradnik J, et al. Enhanced transmissibility, infectivity, and immune
- resistance of the SARS-CoV-2 omicron XBB.1.5 variant. Lancet Infect Dis. 2023;23(3):280-
- 486 281. doi:10.1016/S1473-3099(23)00051-8
- 487 15. Yue C, Song W, Wang L, et al. ACE2 binding and antibody evasion in enhanced
- 488 transmissibility of XBB.1.5. *Lancet Infect Dis.* 2023;23(3):278-280. doi:10.1016/S1473-
- 489 3099(23)00010-5
- 490 16. Bowen JE, Addetia A, Dang HV, et al. Omicron spike function and neutralizing activity
- elicited by a comprehensive panel of vaccines. *Science*. 2022;377(6608):890-894.
- 492 doi:10.1126/science.abq0203
- 493 17. Dijokaite-Guraliuc A, Das R, Zhou D, et al. Rapid escape of new SARS-CoV-2 Omicron
- variants from BA.2-directed antibody responses. *Cell Rep.* 2023;42(4).
- 495 doi:10.1016/j.celrep.2023.112271
- 496 18. Muik A, Lui BG, Quandt J, et al. Progressive loss of conserved spike protein neutralizing
- antibody sites in Omicron sublineages is balanced by preserved T cell immunity. *Cell Rep.*
- 498 2023;42(8). doi:10.1016/j.celrep.2023.112888
- 499 19. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2,
- BO.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med.*
- 501 2023;29(2):344-347. doi:10.1038/s41591-022-02162-x
- 502 20. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2
- BQ and XBB subvariants. Cell. 2023;186(2):279-286.e8. doi:10.1016/j.cell.2022.12.018
- 504 21. Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2
- infection and COVID-19 disease. *Immunol Rev.* 2022;310(1):6-26. doi:10.1111/imr.13091
- 506 22. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*.
- 507 2021;184(4):861-880. doi:10.1016/j.cell.2021.01.007
- 508 23. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19
- vaccines. *Immunol Rev.* 2022;310(1):27-46. doi:10.1111/imr.13089
- 510 24. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity
- to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*.
- 512 2020;183(4):996-1012.e19. doi:10.1016/j.cell.2020.09.038

- 513 25. Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and
- clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
- 515 Nat Med. 2023;29(7):1760-1774. doi:10.1038/s41591-023-02414-4
- 516 26. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the
- 517 Omicron variant. *Nat Med.* 2022;28(3):472-476. doi:10.1038/s41591-022-01700-x
- 518 27. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell
- memory able to cross-recognize variants from Alpha to Omicron. *Cell.* 2022;185(5):847-
- 520 859.e11. doi:10.1016/j.cell.2022.01.015
- 521 28. Gao Y, Cai C, Wullimann D, et al. Immunodeficiency syndromes differentially impact the
- functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. *Immunity*.
- 523 2022;55(9):1732-1746.e5. doi:10.1016/j.immuni.2022.07.005
- 524 29. Ferreira VH, Marinelli T, Ierullo M, et al. Severe Acute Respiratory Syndrome Coronavirus 2
- Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ
- Transplant Recipients. J Infect Dis. 2021;224(11):1849-1860. doi:10.1093/infdis/jiab542
- 30. Rezahosseini O, Hamm SR, Heftdal LD, et al. Humoral and T-cell response 12 months after
- the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics,
- associated factors, and role of SARS-CoV-2 infection. *Front Immunol.* 2023;13. Accessed
- 530 April 24, 2023. https://www.frontiersin.org/articles/10.3389/fimmu.2022.1075423
- 531 31. Thompson EA, Ngecu W, Stoddart L, et al. Heterologous versus homologous boosting elicits
- qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients. *JCI Insight*.
- 533 2023;8(10). doi:10.1172/jci.insight.168470
- 534 32. Altosole T, Rotta G, Uras CRM, Bornheimer SJ, Fenoglio D. An optimized flow cytometry
- protocol for simultaneous detection of T cell activation induced markers and intracellular
- 536 cytokines: Application to SARS-CoV-2 immune individuals. *J Immunol Methods*.
- 537 2023;515:113443. doi:10.1016/j.jim.2023.113443
- 538 33. Poloni C, Schonhofer C, Ivison S, Levings MK, Steiner TS, Cook L. T-cell activation-
- induced marker assays in health and disease. *Immunol Cell Biol.* Published online February
- 540 24, 2023. doi:10.1111/imcb.12636
- 34. Bacher P, Scheffold A. Flow-cytometric analysis of rare antigen-specific T cells. *Cytometry*
- 542 A. 2013;83A(8):692-701. doi:10.1002/cyto.a.22317
- 35. Elias G, Ogunjimi B, Van Tendeloo V. Activation-induced surface proteins in the
- identification of antigen-responsive CD4 T cells. *Immunol Lett.* 2020;219:1-7.
- 545 doi:10.1016/j.imlet.2019.12.006
- 36. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and
- patients with COVID-19. *Nature*. 2020;587(7833):270-274. doi:10.1038/s41586-020-2598-9

- 548 37. Kabbani D, Yotis DM, Ferreira VH, et al. Immunogenicity, Safety, and Breakthrough Severe
- Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019
- Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study.
- *Open Forum Infect Dis.* 2023;10(5):ofad200. doi:10.1093/ofid/ofad200
- 38. Reiss S, Baxter AE, Cirelli KM, et al. Comparative analysis of activation induced marker
- (AIM) assays for sensitive identification of antigen-specific CD4 T cells. *PLOS ONE*.
- 554 2017;12(10):e0186998. doi:10.1371/journal.pone.0186998
- 39. Dan JM, Lindestam Arlehamn CS, Weiskopf D, et al. A Cytokine-Independent Approach To
- Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare
- 557 Antigen-Specific CD4+ T Cells in Blood. *J Immunol Baltim Md* 1950. 2016;197(3):983-993.
- 558 doi:10.4049/jimmunol.1600318
- 40. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection,
- isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without
- requiring knowledge of epitope specificities. *Blood*. 2007;110(1):201-210.
- 562 doi:10.1182/blood-2006-11-056168
- 563 41. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-
- specific CD8+ T cells by a flow cytometric assay for degranulation. *J Immunol Methods*.
- 565 2003;281(1):65-78. doi:10.1016/S0022-1759(03)00265-5
- 566 42. Bowyer G, Rampling T, Powlson J, et al. Activation-induced Markers Detect Vaccine-
- Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical
- Trials. *Vaccines*. 2018;6(3):50. doi:10.3390/vaccines6030050
- 43. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced
- by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol*.
- 571 2020;21(11):1336-1345. doi:10.1038/s41590-020-0782-6
- 572 44. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2
- Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*.
- 574 2020;181(7):1489-1501.e15. doi:10.1016/j.cell.2020.05.015
- 575 45. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to
- 8 months after infection. *Science*. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
- 577 46. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4+ T cells is
- associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA
- vaccination. *Immunity*. 2021;54(9):2133-2142.e3. doi:10.1016/j.immuni.2021.08.001
- 580 47. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and
- 581 CD8+ T cell reactivity in infected or vaccinated individuals. *Cell Rep Med*.
- 582 2021;2(7):100355. doi:10.1016/j.xcrm.2021.100355
- 48. Paul K, Sibbertsen F, Weiskopf D, et al. Specific CD4+ T Cell Responses to Ancestral
- SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant.

- 585 *Front Immunol.* 2022;13. Accessed August 2, 2023.
- https://www.frontiersin.org/articles/10.3389/fimmu.2022.867577
- 587 49. Newell KL, Waldran MJ, Thomas SJ, Endy TP, Waickman AT. Simultaneous analysis of
- antigen-specific B and T cells after SARS-CoV-2 infection and vaccination. *Cytometry*.
- 589 2022;101(6):474-482. doi:10.1002/cyto.a.24563
- 50. Cheung MW, Dayam RM, Shapiro JR, et al. Third and Fourth Vaccine Doses Broaden and
- Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory
- Diseases. *J Immunol*. Published online June 16, 2023:ji2300190.
- 593 doi:10.4049/jimmunol.2300190
- 51. BC Transplant, Provincial Health Services Authority. Medication Guidelines for Solid Organ
- Transplants. Published online May 13, 2021. Accessed July 9, 2023.
- 596 http://www.transplant.bc.ca/health-professionals/transplant-resources/transplant-clinical-
- 597 guidelines/medication-guidelines
- 52. Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung transplantation: state of
- the art ★. Eur J Cardiothorac Surg. 2009;35(6):1045-1055. doi:10.1016/j.ejcts.2009.02.035
- 53. Ng CY, Madsen JC, Rosengard BR, Allan JS. Immunosuppression for lung transplantation.
- 601 Front Biosci J Virtual Libr. 2009;14:1627-1641.
- 602 54. Meshram HS, Kute V, Rane H, et al. Humoral and cellular response of COVID-19 vaccine
- among solid organ transplant recipients: A systematic review and meta-analysis. *Transpl*
- 604 Infect Dis. Published online August 12, 2022:e13926. doi:10.1111/tid.13926
- 55. Schaenman J, Byford H, Grogan T, et al. Impact of solid organ transplant status on outcomes
- of hospitalized patients with COVID-19 infection. *Transpl Infect Dis.* 2022;24(4):e13853.
- doi:10.1111/tid.13853
- 56. Czesnikiewicz-Guzik M, Lee WW, Cui D, et al. T cell subset-specific susceptibility to aging.
- 609 Clin Immunol Orlando Fla. 2008;127(1):107-118. doi:10.1016/j.clim.2007.12.002
- 57. Moro-García MA, Alonso-Arias R, López-Larrea C. When Aging Reaches CD4+ T-Cells:
- Phenotypic and Functional Changes. *Front Immunol.* 2013;4:107.
- doi:10.3389/fimmu.2013.00107
- 58. Weinberger B, Lazuardi L, Weiskirchner I, et al. Healthy aging and latent infection with
- 614 CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in the elderly. *Hum*
- 615 *Immunol.* 2007;68(2):86-90. doi:10.1016/j.humimm.2006.10.019
- 59. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism
- and function of CD40/CD40L engagement in the immune system. *Immunol Rev*.
- 618 2009;229(1):152-172. doi:10.1111/j.1600-065X.2009.00782.x
- 619 60. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol*. 2022;23(2):186-
- 620 193. doi:10.1038/s41590-021-01122-w

61. Jeong HW, Kim SM, Jung MK, et al. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection. Cell Rep Med. 2022;3(10). doi:10.1016/j.xcrm.2022.100764 62. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022;603(7901):488-492. doi:10.1038/s41586-022-04460-3 63. Qui M, Bert NL, Chan WPW, et al. Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies. J Clin Invest. 2022;132(12). doi:10.1172/JCI159500 64. Tye EXC, Jinks E, Haigh TA, et al. Mutations in SARS-CoV-2 spike protein impair epitopespecific CD4+ T cell recognition. Nat Immunol. 2022;23(12):1726-1734. doi:10.1038/s41590-022-01351-7 65. Rosa DS, Ribeiro SP, Cunha-Neto E. CD4+ T Cell Epitope Discovery and Rational Vaccine Design. Arch Immunol Ther Exp (Warsz). 2010;58(2):121-130. doi:10.1007/s00005-010-0067-0 66. Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep Med. 2021;2(7). doi:10.1016/j.xcrm.2021.100354 67. Ogbe A, Kronsteiner B, Skelly DT, et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. *Nat Commun*. 2021;12(1):2055. doi:10.1038/s41467-021-21856-3

Table 1. Study Cohort Characteristics

Characteristic	n (%) or median [IQR] ^a			Total
	Kidney	Liver	Lung	
Sample size	16	16	10	42
Pre-2nd dose	5 (31%)	12 (75%)	4 (40%)	21 (50%)
Post-2nd dose	16 (100%)	16 (100%)	8 (80%)	40 (95%)
Six months post-1st dose	3 (19%)	4 (25%)	4 (40%)	11 (26%)
Post-3rd dose	14 (88%)	11 (69%)	8 (80%)	33 (79%)
One year post-1st dose	14 (88%)	9 (56%)	9 (90%)	32 (76%)
Neither 4th dose nor COVID-19	1 (6%)	4 (25%)	1 (10%)	6 (14%)
Post-4th dose (no COVID-19)	7 (44%)	4 (25%)	4 (40%)	15 (36%)
Hybrid (4th dose + COVID-19)	6 (38%)	1 (6%)	0 (0%)	7 (17%)
COVID-19 (no 4th dose)	0 (0%)	0 (0%)	4 (40%)	4 (10%)
Sample collection timing				
1st dose to pre-2nd dose sample (days)	73	71	70	70
	[40, 84]	[47, 76]	[69, 75]	[53, 79]
2nd dose to post-2nd dose sample (days)	29	29	34	29
	[26, 33]	[28, 33]	[29, 35]	[26, 34]
2nd dose to 6 month sample (days)	105	146	105	109
		[128, 152]	[102, 108]	[100, 134]
3rd dose to post-3rd dose sample (days)	33	31	32	32
	[28, 40]	[29, 36]	[28, 36]	[28, 39]
3rd dose to 1 year sample (no 4th dose or COVID-19) (days)	232	203	217	211
		[194, 209]		[200, 216]
4th dose to 1 year sample (no COVID-19) (days)	28	22	30	27
	[27, 39]	[20, 27]	[25, 35]	[22, 39]
4th dose to 1 year sample (hybrid) (days)	34	36		35
	[26, 39]			[28, 38]
COVID-19 to 1 year sample (hybrid) (days)	135	118		126
	[110, 151]			[111, 148]
Age	55	62	56	58
T:	[46, 66]	[50, 66]	[49, 65]	[47, 66]
Time since transplant (y)	4.6	8.7	9.0	6.8
Sex	[2.8, 8.0]	[4.5, 13.9]	[4.3, 14.1]	[3.2, 12.9]
Female	8 (50%)	0 (560/)	5 (500/)	22 (520/)
Male	8 (50%) 8 (50%)	9 (56%) 7 (44%)	5 (50%) 5 (50%)	22 (52%) 20 (48%)
	0 (3070)	/ (4470)	3 (30%)	20 (48%)
Vaccinations	16 (1000/)	16 (1000/)	10 (1000/)	42 (1000/)
1st dose	16 (100%)	16 (100%)	10 (100%)	42 (100%)
Moderna	2 (13%)	6 (38%)	0 (0%)	8 (19%)
Pfizer-BioNTech	14 (88%)	10 (63%)	10 (100%)	34 (81%)

2nd dose	16 (100%)	16 (100%)	10 (100%)	42 (100%)
Moderna	2 (13%)	8 (50%)	0 (0%)	10 (24%)
Pfizer-BioNTech	14 (88%)	8 (50%)	10 (100%)	32 (76%)
3rd dose	15 (94%)	13 (81%)	10 (100%)	38 (90%)
Moderna	6 (38%)	11 (69%)	6 (60%)	23 (55%)
Pfizer-BioNTech	9 (56%)	2 (13%)	4 (40%)	15 (36%)
4th dose	14 (88%)	12 (75%)	9 (90%)	35 (83%)
Moderna	11 (69%)	11 (69%)	7 (70%)	29 (69%)
Pfizer-BioNTech	3 (19%)	1 (6%)	2 (20%)	6 (14%)
Immunosuppression at enrollment				
Prednisone	10 (63%)	0 (0%)	10 (100%)	20 (48%)
Cyclosporine	0 (0%)	1 (6%)	0 (0%)	1 (2%)
Tacrolimus	16 (69%)	11 (69%)	10 (100%)	35 (83%)
Mycophenolate mofetil or mycophenolate sodium	12 (44%)	7 (44%)	8 (80%)	27 (64%)
Azathioprine	3 (19%)	1 (6%)	1 (10%)	5 (12%)
Sirolimus	0 (0%)	3 (19%)	0 (0%)	3 (7%)

^aOnly medians are reported when groups have fewer than n = 4

Table 2. Correlations of anti-RBD titres with T cell activation-induced marker responses

Timepoint	Variant	Spearman's r	P-value	Significance
CD4+ T cells (CD134+/CD69+)				
pre-2nd	Ancestral	0.2369	0.2884	ns
pre-2nd	BA.4/5	0.4066	0.0604	ns
post-2nd	Ancestral	0.3064	0.0514	ns
post-2nd	BA.4/5	0.3091	0.0493	*
6 months	Ancestral	0.8028	0.0082	**
6 months	BA.4/5	0.6554	0.0454	*
post-3rd	Ancestral	0.6755	< 0.0001	***
post-3rd	BA.4/5	0.6411	< 0.0001	****
CD0 T - 11 (CD127 /CD(0)				
CD8+ T cells (CD137+/CD69+)		0.4050	0.0504	
pre-2nd	Ancestral	0.4273	0.0534	ns
pre-2nd	BA.4/5	0.3288	0.1456	ns
post-2nd	Ancestral	0.2832	0.0727	ns
post-2nd	BA.4/5	0.2726	0.0847	ns
6 months	Ancestral	0.6457	0.0512	ns
6 months	BA.4/5	0.6241	0.0591	ns
post-3rd	Ancestral	0.3527	0.0441	*
post-3rd	BA.4/5	0.3313	0.0596	ns

ns, non-significant; *p <0.05, **p <0.01; ***p <0.001; ****p <0.0001







Figure 1. Second and third vaccine doses induce durable Omicron BA.4/5-specific T cell responses in solid-organ transplant recipients. A) PBMC samples from solid organ transplant recipients (SOTRs, n = 42) immunized with COVID-19 mRNA vaccines were collected at presecond dose, post-second dose, six months post-first dose, post-third dose and one-year timepoints. B) Representative flow cytometry data showing T cell activation-induced marker (AIM) responses to the ancestral strain of SARS-CoV-2 in one donor after three doses of a COVID-19 mRNA vaccine. Samples were stimulated with 1 µg/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides for 20 h. CD4+ T cell activation-induced marker (AIM) responses were measured as frequencies of CD134+/CD25+, CD134+/CD69+ or CD137+/CD69+ events among CD4+ T cells. CD8+ AIM responses were measured as frequencies of CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+ events among CD8+ T cells. All data represent net AIM+ frequencies after subtracting the equivalent AIM+ frequency in the DMSO-stimulated control. C) Time course of CD4+ and CD8+ T cell AIM responses to ancestral SARS-CoV-2 and BA.4/5 in SOTRs. Participants who had already received a third dose were excluded at the six-month timepoint, and participants who received a fourth dose or developed COVID-19 were excluded at the one-year timepoint to model the natural history of the vaccine-induced T cell response. P-values represent Dunnett's multiple comparisons test following a mixed effects analysis on log₂-transformed AIM+ frequencies.

Figure 2







728

729

730

731

732

733734

735

736 737

738

739 740

741742

743

744

745

746

747

748

Figure 2. A fourth vaccine dose enhances SARS-CoV-2-specific T cell responses in solid organ transplant recipients. PBMCs from solid organ transplant recipients (SOTRs) were collected at post-third dose and one year post-first dose (6-8 months post-third dose) timepoints and stimulated with 1 µg/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides for 20 h. T cell activation-induced marker (AIM) responses were quantified as CD134+/CD69+ or CD137+/CD69+ frequencies among CD4+ and CD8+ T cells, respectively, after subtraction of the equivalent AIM+ frequency in the DMSO-stimulated control. A) At the one-year timepoint, SOTRs were grouped as having received neither a fourth dose nor a contracting COVID-19 (controls, n = 6), having received a fourth monovalent COVID-19 mRNA vaccine dose within 3-6 weeks of sample collection (fourth dose, n = 15), or a fourth dose and symptomatic COVID-19 (hybrid, n = 7). Patients who had only COVID-19 infection (n = 4) were excluded due to insufficient sample size. B) Evolution of CD4+ and CD8+ T cell AIM responses in from the post-third dose to one-year timepoint within fourth dose, hybrid and control groups of SOTRs. Paired Wilcoxon signed-rank test p-values are shown. C) Effect of a fourth dose or hybrid immunity on CD4+ and CD8+ T cell AIM responses in SOTRs. Changes from post-third dose to one-year timepoints are compared between fourth dose, hybrid and control groups. P-values represent Dunn's multiple comparisons test following a Kruskal-Wallis test.

Figure 3




Figure 3. T cell activation-induced marker responses to Omicron BA.4/5 are weaker than responses to ancestral SARS-CoV-2 in solid organ transplant recipients. Paired comparisons of CD4+ (**A**) and CD8+ (**B**) T cell AIM responses to Omicron BA.4/5 and ancestral SARS-CoV-2, measured after three doses of a COVID-19 mRNA vaccine, in solid organ transplant recipients (n = 33). Following a 20-h stimulation of patient PBMCs with 1 μg/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides, CD4+ T cell activation-induced marker (AIM) responses were quantified as frequencies of CD134+/CD25+, CD134+/CD69+ or CD137+/CD69+ events among CD4+ T cells, while CD8+ AIM responses were measured as frequencies of CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+ events among CD8+ T cells, after subtracting the equivalent AIM+ frequency in the DMSO-stimulated control. Wilcoxon signed-rank test p-values are shown.

Figure 4




Figure 4. Prednisone, lung transplantation and older age are associated with weaker T cell responses to COVID-19 vaccination. Post-third dose CD4+ and CD8+ T cell activationinduced marker (AIM) responses to SARS-CoV-2 ancestral and Omicron BA.4/5 variants are shown in solid-organ transplant recipients. Patient PBMCs were stimulated for 20 h with 1 ug/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides, and T cell activationinduced marker responses were quantified by flow cytometry as frequencies of CD134+/CD69+ events among CD4+ T cells, or CD137+/CD69+ events among CD8+ T cells, after subtracting the equivalent AIM+ frequency in the DMSO-stimulated control. A) Mann-Whitney U-test comparing AIM responses between patients receiving baseline prednisone (n = 17) and those not receiving prednisone (n = 16). Symbols differentiate between kidney (black circles), liver (red squares) and lung (blue triangles) transplant recipients. B) Comparisons of AIM responses between kidney (n = 14), liver (n = 11) and lung (n = 8) transplant recipients. Dunn's multiple comparisons p-values are shown following a Kruskal-Wallis test. C) Semilogarithmic regression analysis of the relationship between age and T cell AIM responses, testing the null hypothesis of the slope being equal to zero.




Figure 5. SARS-CoV-2-specific T cell activation-induced marker responses correlate with Spike-specific antibody titres in solid organ transplant recipients. Relationships of T cell activation-induced marker (AIM) responses with previously published anti-Spike binding and neutralizing antibodies are shown in solid organ transplant recipients⁹. PBMCs were collected from COVID-19-vaccinated SOTRs at pre-second dose, post-second dose, six months post-first dose and post-fourth dose timepoints. AIM responses are shown as frequencies of CD134+/CD69+ or CD137+/CD69+ events among CD4+ or CD8+ T cells, respectively, following stimulation for 20 h with 1 µg/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides, after subtracting the equivalent AIM+ frequency in the DMSO-stimulated control. A) Spearman's correlations of CD4+ and CD8+ T cell activation-induced marker responses to ancestral or Omicron BA.4/5 variants of SARS-CoV-2 with circulating anti-Spike antibody titres. Correlations were analyzed separately at pre-second dose (green circles, n = 21), post-second dose (blue triangles, n = 40), six months post-first dose (red squares, n = 10) and third dose (black triangles, n = 33) vaccination timepoints. B) Log-log regression analysis of post-second dose CD4+ AIM responses and post-third dose anti-RBD antibody titres in SOTRs who had no detectable post-second dose antibody titres, testing the null hypothesis of slope being equal to zero. C) Comparison of post-third dose and post-fourth dose CD4+ and CD8+ T cell AIM responses to BA.4/5 in patients with (nAbs) or without (no nAbs) detectable BA.4/5 neutralization titres. Groups were compared by unpaired two-sample t-tests on log₂-transformed AIM frequencies.




Figure 6. The SARS-CoV-2 variant XBB.1.5 partially escapes recognition by vaccine-induced T cells in solid organ transplant recipients. CD4+ and CD8+ T cell AIM responses to SARS-CoV-2 ancestral strain Spike protein and XBB1.5 Spike protein, measured prior to a second dose and after three doses of a COVID-19 mRNA vaccine in solid organ transplant recipients (n = 10). Following a 44-h stimulation of patient PBMCs with 0.5 μg/mL SARS-CoV-2 ancestral strain or XBB.1.5 Spike protein, CD4+ T cell activation-induced marker (AIM) responses were quantified as frequencies of CD134+/CD69+ events among CD4+ T cells, while CD8+ AIM responses were measured as frequencies of CD137+/CD69+ events among CD8+ T cells, after subtraction of the equivalent AIM+ frequency in the PBS-stimulated control. Paired Wilcoxon signed-rank test p-values are shown. A) Comparisons of AIM responses between presecond dose and post-third dose timepoints. B) Comparisons of AIM responses to ancestral SARS-CoV-2 and XBB.1.5.